These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 14518186)

  • 1. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
    Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
    Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
    Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
    Straetmans N; Ma DD; Nevell DF; Arthur C
    Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
    Buesche G; Ganser A; Schlegelberger B; von Neuhoff N; Gadzicki D; Hecker H; Bock O; Frye B; Kreipe H
    Leukemia; 2007 Dec; 21(12):2420-7. PubMed ID: 17805334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
    Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
    Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
    Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of chronic myeloid leukemia with interferon-alpha].
    Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H
    Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
    Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
    Buesche G; Freund M; Hehlmann R; Georgii A; Ganser A; Hecker H; Heimpel H; Fonatsch C; Heinze B; Pfirrmann M; Holgado S; Schmeil A; Tobler A; Hasford J; Buhr T; Kreipe HH;
    Leukemia; 2004 Sep; 18(9):1460-7. PubMed ID: 15284854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.
    Dolgikh TY; Domnikova NP; Tornuev YV; Vinogradova EV; Krinitsyna YM
    Bull Exp Biol Med; 2017 Feb; 162(4):483-487. PubMed ID: 28239786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathological characteristics of leukemia patients with secondary myelofibrosis and their relationship with the prognosis of disease].
    Guan JH; Wang XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):311-4. PubMed ID: 23628022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular composition and reticulin fibrosis in chronic myeloid leukaemia.
    Ghosh K; Varma N; Varma S; Dash S
    Indian J Cancer; 1988 Sep; 25(3):128-35. PubMed ID: 3224984
    [No Abstract]   [Full Text] [Related]  

  • 17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful low-dose etoposide therapy for a case of myelofibrosis with chronic myelogenous leukemia megakaryocytic predominance type].
    Katayama T; Masuoka H; Yoshida M; Watanabe R; Nishiwaki K; Shimada T; Kaito K; Ochiai S; Kobayashi M; Sakai O
    Rinsho Ketsueki; 1992 Apr; 33(4):488-93. PubMed ID: 1602613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.